Table 1.
Patient characteristics.
| Characteristics | Overall | Patients with Negative LNs | Patients with Positive LNs |
|---|---|---|---|
| n = 50 | n = 32 (64%) | n = 18 (36%) | |
| Age, years (median) | 69.5 | 68.5 | 71.5 |
| IQR | 64–73 | 64–73 | 64.5–73 |
| Total PSA, ng/mL (median) | 10.8 | 9.8 | 12.0 |
| IQR | 7.4–19.2 | 6.9–14.7 | 8.3–30.1 |
| Number of LNs removed (median) | 18 | 19 | 17.5 |
| IQR | 15–23 | 15–23 | 16–22 |
| Number of SLNs removed (median) | 9 | 9 | 10 |
| IQR | 6–12 | 5–11 | 7–12 |
| Number of positive LNs (median) | 2 | ||
| IQR | 1–3 | ||
| Tumor stage (%) | |||
| T1c | 28 (56) | 22 (68.8) | 6 (33.3) |
| T2a | 2 (4) | 1 (3.1) | 1 (5.6) |
| T2b | 6 (12) | 4 (12.5) | 2 (11.1) |
| T2c | 12 (24) | 5 (15.6) | 7 (38.9) |
| T3 | 2 (4) | 0 (0) | 2 (11.1) |
| Biopsy Gleason score (%) | |||
| 6 (3 + 3) | 8 (16) | 8 (25.0) | 0 (0) |
| 7 (3 + 4) | 26 (52) | 18 (56.3) | 8 (44.4) |
| 7 (4 + 3) | 6 (12) | 5 (15.6) | 1 (5.6) |
| ≥8 | 10 (20) | 1 (3.1) | 9 (50.0) |
| Postoperative Gleason score (%) | |||
| 6 (3 + 3) | 2 (4) | 2 (6.3) | 0 (0) |
| 7 (3 + 4) | 23 (46) | 19 (59.4) | 4 (22.2) |
| 7 (4 + 3) | 14 (28) | 8 (25.0) | 6 (33.3) |
| ≥8 | 11 (22) | 3 (9.4) | 8 (44.4) |
| Pathologic stage (%) | |||
| pT2 | 24 (48) | 22 (68.8) | 2 (11.1) |
| pT3a | 12 (24) | 7 (21.9) | 5 (27.8) |
| pT3b | 12 (24) | 3 (9.4) | 9 (50.0) |
| pT4 | 2 (4) | 0 (0) | 2 (11.1) |
IQR, Interquartile range; (S)LN, (sentinel) lymph node; PSA, prostate-specific antigen.